Comparing Tvardi Therapeutics (TVRD) & Its Peers

Tvardi Therapeutics (NASDAQ:TVRD) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Tvardi Therapeutics to similar businesses based on the strength of its profitability, earnings, institutional ownership, risk, dividends, valuation and analyst recommendations.

Volatility & Risk

Tvardi Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics’ rivals have a beta of -0.13, indicating that their average stock price is 113% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Tvardi Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1	0	6	1	2.88
Tvardi Therapeutics Competitors	7840	13794	25805	1039	2.41

Tvardi Therapeutics currently has a consensus target price of $9.40, suggesting a potential upside of 696.61%. As a group, “Pharmaceuticals” companies have a potential upside of 24.65%. Given Tvardi Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than its rivals.

Profitability

This table compares Tvardi Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Tvardi Therapeutics Competitors	-2,400.69%	-221.80%	-15.58%

Institutional and Insider Ownership

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Tvardi Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tvardi Therapeutics	$7.14 million	-$18.21 million	-0.42
Tvardi Therapeutics Competitors	$3.56 billion	$3.20 billion	562.76

Tvardi Therapeutics’ rivals have higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Tvardi Therapeutics beats its rivals on 8 of the 13 factors compared.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.